{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:29:55Z","timestamp":1793248195297,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s11255-020-02546-3","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T07:04:08Z","timestamp":1594623848000},"page":"2113-2122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Fabry disease: where are we now?"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-7716","authenticated-orcid":false,"given":"K.","family":"Turkmen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Baloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"issue":"1","key":"2546_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R (2009) Fabry disease. Pharmacol Ther 122(1):65\u201377. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.01.003","journal-title":"Pharmacol Ther"},{"key":"2546_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","volume":"10","author":"W Anderson","year":"1898","unstructured":"Anderson W (1898) A case of angiokeratoma. Br J Dermatol 10:113\u2013117","journal-title":"Br J Dermatol"},{"key":"2546_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01986897","volume":"43","author":"J Fabry","year":"1898","unstructured":"Fabry J (1898) Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica). Arch Derm Syph 43:187\u2013200","journal-title":"Arch Derm Syph"},{"issue":"9","key":"2546_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8(9):539\u2013548. https:\/\/doi.org\/10.1097\/01.gim.0000237866.70357.c6","journal-title":"Genet Med"},{"issue":"8","key":"2546_CR5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1742-1241.2011.02695.x","volume":"65","author":"MA Barba-Romero","year":"2011","unstructured":"Barba-Romero MA, Rivera-Gallego A, Pintos-Morell G (2011) Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS). Int J Clin Pract 65(8):903\u2013910. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02695.x","journal-title":"Int J Clin Pract"},{"issue":"1","key":"2546_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31\u201340. https:\/\/doi.org\/10.1086\/504601","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2546_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","volume":"28","author":"TR Hsu","year":"2018","unstructured":"Hsu TR, Niu DM (2018) Fabry disease: review and experience during newborn screening. Trends Cardiovasc Med 28(4):274\u2013281. https:\/\/doi.org\/10.1016\/j.tcm.2017.10.001","journal-title":"Trends Cardiovasc Med"},{"issue":"6","key":"2546_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1159\/000452605","volume":"41","author":"K Turkmen","year":"2016","unstructured":"Turkmen K, Guclu A, Sahin G, Kocyigit I, Demirtas L, Erdur FM, Sengul E, Ozkan O, Emre H, Turgut F, Unal H, Karaman M, Acikel C, Esen H, Balli E, Bitirgen G, Tonbul HZ, Yilmaz MI, Ortiz A (2016) The prevalence of fabry disease in patients with chronic kidney disease in Turkey: the TURKFAB study. Kidney Blood Press Res 41(6):1016\u20131024. https:\/\/doi.org\/10.1159\/000452605","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"2546_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000496620","volume":"142","author":"SF Yalin","year":"2019","unstructured":"Yalin SF, Eren N, Sinangil A, Yilmaz VT, Tatar E, Ucar AR, Sevinc M, Can O, Gurkan A, Arik N, Alisir Ecder S, Uyar M, Yasar M, Gulcicek S, Mese M, Dheir H, Cakir U, Koksal Cevher S, Turkmen K, Guven B, Guven Taymez D, Erkalma Senates B, Ecder T, Kocak H, Uslu A, Demir E, Basturk T, Ogutmen MB, Kinalp C, Dursun B, Bicik Bahcebasi Z, Sipahi S, Dede F, Oruc M, Caliskan Y, Genc A, Yelken B, Altiparmak MR, Turkmen A, Seyahi N (2019) Fabry disease prevalence in renal replacement therapy in Turkey. Nephron 142(1):26\u201333. https:\/\/doi.org\/10.1159\/000496620","journal-title":"Nephron"},{"issue":"Suppl 2","key":"2546_CR10","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.3816\/CCC.2007.s.003","volume":"6","author":"C Eng","year":"2007","unstructured":"Eng C (2007) Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. Clin Colorectal Cancer 6(Suppl 2):S53\u201359","journal-title":"Clin Colorectal Cancer"},{"key":"2546_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30","journal-title":"Orphanet J Rare Dis"},{"key":"2546_CR12","unstructured":"Mehta A, Widmer U (2006) Natural history of Fabry disease. doi:NBK11572 [bookaccession]"},{"issue":"11","key":"2546_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11(11):790\u2013796. https:\/\/doi.org\/10.1097\/GIM.0b013e3181bb05bb","journal-title":"Genet Med"},{"issue":"1","key":"2546_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89(1):44\u201354. https:\/\/doi.org\/10.1111\/cge.12613","journal-title":"Clin Genet"},{"issue":"3","key":"2546_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ndt\/gfs526","volume":"28","author":"W Terryn","year":"2013","unstructured":"Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C (2013) Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 28(3):505\u2013517. https:\/\/doi.org\/10.1093\/ndt\/gfs526","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2546_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry Outcome Survey. J Med Genet 46(8):548\u2013552. https:\/\/doi.org\/10.1136\/jmg.2008.065904","journal-title":"J Med Genet"},{"issue":"6","key":"2546_CR17","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1016\/j.ijcard.2012.06.069","volume":"167","author":"W Terryn","year":"2013","unstructured":"Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B, Hemelsoet D, Pascale H, De Backer J, De Paepe A, Poppe B, Vanholder R (2013) Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol 167(6):2555\u20132560. https:\/\/doi.org\/10.1016\/j.ijcard.2012.06.069","journal-title":"Int J Cardiol"},{"issue":"7","key":"2546_CR18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24(7):2102\u20132111. https:\/\/doi.org\/10.1093\/ndt\/gfp031","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2546_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2215\/CJN.03130411","volume":"7","author":"S Feriozzi","year":"2012","unstructured":"Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M (2012) The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 7(1):60\u201369. https:\/\/doi.org\/10.2215\/CJN.03130411","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2546_CR20","first-page":"784","volume":"47","author":"H Sakuraba","year":"1990","unstructured":"Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop DF, Desnick RJ, Suzuki Y (1990) Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 47(5):784\u2013789","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2546_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/humu.9520","volume":"29","author":"M Shimotori","year":"2008","unstructured":"Shimotori M, Maruyama H, Nakamura G, Suyama T, Sakamoto F, Itoh M, Miyabayashi S, Ohnishi T, Sakai N, Wataya-Kaneda M, Kubota M, Takahashi T, Mori T, Tamura K, Kageyama S, Shio N, Maeba T, Yahagi H, Tanaka M, Oka M, Sugiyama H, Sugawara T, Mori N, Tsukamoto H, Tamagaki K, Tanda S, Suzuki Y, Shinonaga C, Miyazaki J, Ishii S, Gejyo F (2008) Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat 29(2):331. https:\/\/doi.org\/10.1002\/humu.9520","journal-title":"Hum Mutat"},{"issue":"5","key":"2546_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"6","key":"2546_CR23","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/cge.13233","volume":"93","author":"M du Moulin","year":"2018","unstructured":"du Moulin M, Muschol N (2018) p.D313Y is more than just a polymorphism in Fabry disease. Clin Genet 93(6):1258. https:\/\/doi.org\/10.1111\/cge.13233","journal-title":"Clin Genet"},{"issue":"6","key":"2546_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/cge.13237","volume":"93","author":"D Oder","year":"2018","unstructured":"Oder D, Wanner C, Nordbeck P (2018) The D313Y genotype-pathogenic mutation or polymorphism? Clin Genet 93(6):1257. https:\/\/doi.org\/10.1111\/cge.13237","journal-title":"Clin Genet"},{"key":"2546_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-019-00663-6","author":"I Capuano","year":"2019","unstructured":"Capuano I, Garofalo C, Buonanno P, Pinelli M, Di Risi T, Feriozzi S, Riccio E, Pisani A (2019) Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995\u20132019. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-019-00663-6","journal-title":"J Nephrol"},{"issue":"3","key":"2546_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/cge.12261","volume":"86","author":"M Rigoldi","year":"2014","unstructured":"Rigoldi M, Concolino D, Morrone A, Pieruzzi F, Ravaglia R, Furlan F, Santus F, Strisciuglio P, Torti G, Parini R (2014) Intrafamilial phenotypic variability in four families with Anderson\u2013Fabry disease. Clin Genet 86(3):258\u2013263. https:\/\/doi.org\/10.1111\/cge.12261","journal-title":"Clin Genet"},{"issue":"27","key":"2546_CR27","doi-asserted-by":"publisher","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","volume":"285","author":"EB Vitner","year":"2010","unstructured":"Vitner EB, Platt FM, Futerman AH (2010) Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 285(27):20423\u201320427. https:\/\/doi.org\/10.1074\/jbc.R110.134452","journal-title":"J Biol Chem"},{"issue":"2","key":"2546_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00401-007-0296-4","volume":"115","author":"JA Castaneda","year":"2008","unstructured":"Castaneda JA, Lim MJ, Cooper JD, Pearce DA (2008) Immune system irregularities in lysosomal storage disorders. Acta Neuropathol 115(2):159\u2013174. https:\/\/doi.org\/10.1007\/s00401-007-0296-4","journal-title":"Acta Neuropathol"},{"key":"2546_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.0105-2896.2005.00310.x","volume":"207","author":"LC Hsing","year":"2005","unstructured":"Hsing LC, Rudensky AY (2005) The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev 207:229\u2013241. https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00310.x","journal-title":"Immunol Rev"},{"issue":"4","key":"2546_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ymgme.2013.01.018","volume":"108","author":"CS Pereira","year":"2013","unstructured":"Pereira CS, Azevedo O, Maia ML, Dias AF, Sa-Miranda C, Macedo MF (2013) Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab 108(4):241\u2013248. https:\/\/doi.org\/10.1016\/j.ymgme.2013.01.018","journal-title":"Mol Genet Metab"},{"issue":"8","key":"2546_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1084\/jem.188.8.1529","volume":"188","author":"FM Spada","year":"1998","unstructured":"Spada FM, Koezuka Y, Porcelli SA (1998) CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188(8):1529\u20131534. https:\/\/doi.org\/10.1084\/jem.188.8.1529","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"2546_CR32","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1007\/s10545-009-1060-9","volume":"32","author":"P Rozenfeld","year":"2009","unstructured":"Rozenfeld P, Agriello E, De Francesco N, Martinez P, Fossati C (2009) Leukocyte perturbation associated with Fabry disease. J Inherit Metab Dis 32(Suppl 1):S67\u201377. https:\/\/doi.org\/10.1007\/s10545-009-1060-9","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2546_CR33","doi-asserted-by":"publisher","first-page":"c61","DOI":"10.1159\/000101799","volume":"106","author":"A Petermann","year":"2007","unstructured":"Petermann A, Floege J (2007) Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin Pract 106(2):c61\u201366. https:\/\/doi.org\/10.1159\/000101799","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"2546_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/ckj\/sfy081","volume":"12","author":"MD Sanchez-Nino","year":"2019","unstructured":"Sanchez-Nino MD, Perez-Gomez MV, Valino-Rivas L, Torra R, Ortiz A (2019) Podocyturia: why it may have added value in rare diseases. Clin Kidney J 12(1):49\u201352. https:\/\/doi.org\/10.1093\/ckj\/sfy081","journal-title":"Clin Kidney J"},{"issue":"1","key":"2546_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ckj\/sfy053","volume":"12","author":"H Trimarchi","year":"2019","unstructured":"Trimarchi H, Canzonieri R, Costales-Collaguazo C, Politei J, Stern A, Paulero M, Gonzalez-Hoyos I, Schiel A, Rengel T, Forrester M, Lombi F, Pomeranz V, Iriarte R, Muryan A, Zotta E (2019) Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes. Clin Kidney J 12(1):53\u201360. https:\/\/doi.org\/10.1093\/ckj\/sfy053","journal-title":"Clin Kidney J"},{"issue":"1","key":"2546_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12967-016-1049-8","volume":"14","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H, Canzonieri R, Schiel A, Costales-Collaguazo C, Politei J, Stern A, Paulero M, Rengel T, Andrews J, Forrester M, Lombi M, Pomeranz V, Iriarte R, Muryan A, Zotta E, Sanchez-Nino MD, Ortiz A (2016) Increased urinary CD80 excretion and podocyturia in Fabry disease. J Transl Med 14(1):289. https:\/\/doi.org\/10.1186\/s12967-016-1049-8","journal-title":"J Transl Med"},{"issue":"1","key":"2546_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C Tondel","year":"2013","unstructured":"Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24(1):137\u2013148. https:\/\/doi.org\/10.1681\/ASN.2012030316","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2546_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5414\/CN108986","volume":"87","author":"N Yang","year":"2017","unstructured":"Yang N, Wang X, Xu F, Zeng C, Wang J (2017) Clinical and pathological characteristics of Fabry disease combined with IgA nephropathy in Chinese patients. Clin Nephrol 87(4):188\u2013195. https:\/\/doi.org\/10.5414\/CN108986","journal-title":"Clin Nephrol"},{"issue":"13","key":"2546_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5414\/CNP88FX28","volume":"88","author":"B Vujkovac","year":"2017","unstructured":"Vujkovac B (2017) Fabry disease: diagnostic methods in nephrology practice. Clin Nephrol 88(13):44\u201347. https:\/\/doi.org\/10.5414\/CNP88FX28","journal-title":"Clin Nephrol"},{"issue":"2","key":"2546_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1023\/a:1014545521753","volume":"11","author":"RL Bennett","year":"2002","unstructured":"Bennett RL, Hart KA, O'Rourke E, Barranger JA, Johnson J, MacDermot KD, Pastores GM, Steiner RD, Thadhani R (2002) Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns 11(2):121\u2013146. https:\/\/doi.org\/10.1023\/a:1014545521753","journal-title":"J Genet Couns"},{"issue":"8","key":"2546_CR41","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105(8):2812\u20132817. https:\/\/doi.org\/10.1073\/pnas.0712309105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"2546_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC (2017) Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab 120(1\u20132):57\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2016.10.006","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2546_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC (2018) Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab 123(2):148\u2013153. https:\/\/doi.org\/10.1016\/j.ymgme.2017.07.002","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2546_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81(2):122\u2013138. https:\/\/doi.org\/10.1097\/00005792-200203000-00003","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2546_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52(5):353\u2013358. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102797","journal-title":"J Med Genet"},{"key":"2546_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","volume":"3","author":"M Beck","year":"2015","unstructured":"Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, Ramaswami U, West M, Wijatyk A, Giugliani R (2015) Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Mol Genet Metab Rep 3:21\u201327. https:\/\/doi.org\/10.1016\/j.ymgmr.2015.02.002","journal-title":"Mol Genet Metab Rep"},{"key":"2546_CR47","doi-asserted-by":"publisher","first-page":"CD006663","DOI":"10.1002\/14651858.CD006663.pub4","volume":"7","author":"R El Dib","year":"2016","unstructured":"El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC (2016) Enzyme replacement therapy for Anderson\u2013Fabry disease. Cochrane Database Syst Rev 7:CD006663. https:\/\/doi.org\/10.1002\/14651858.CD006663.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2546_CR48","doi-asserted-by":"publisher","first-page":"e0173358","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F (2017) Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE 12(3):e0173358. https:\/\/doi.org\/10.1371\/journal.pone.0173358","journal-title":"PLoS ONE"},{"key":"2546_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymgmr.2017.10.008","volume":"14","author":"M Beck","year":"2018","unstructured":"Beck M, Hughes D, Kampmann C, Pintos-Morell G, Ramaswami U, West ML, Giugliani R (2018) Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events. Mol Genet Metab Rep 14:31\u201335. https:\/\/doi.org\/10.1016\/j.ymgmr.2017.10.008","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2546_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345(1):9\u201316. https:\/\/doi.org\/10.1056\/NEJM200107053450102","journal-title":"N Engl J Med"},{"issue":"3","key":"2546_CR51","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jimd.12052","volume":"42","author":"JB Hennermann","year":"2019","unstructured":"Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T (2019) Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease. J Inherit Metab Dis 42(3):527\u2013533. https:\/\/doi.org\/10.1002\/jimd.12052","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"2546_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, Ruderfer I, Aviezer D, Shaaltiel Y (2015) Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab 114(2):259\u2013267. https:\/\/doi.org\/10.1016\/j.ymgme.2014.08.002","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2546_CR53","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R (2016) Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med 375(6):545\u2013555. https:\/\/doi.org\/10.1056\/NEJMoa1510198","journal-title":"N Engl J Med"},{"key":"2546_CR54","doi-asserted-by":"publisher","first-page":"i346","DOI":"10.1093\/ndt\/gfy104.SP004","volume":"33","author":"RBD Schifmann","year":"2018","unstructured":"Schifmann RBD, Germain D et al (2018) Efects of long-term migalastat treatment on renal function by baseline proteinuria in patients with Fabry disease. Nephrol Dial Transplant 33:i346\u2013i347","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2546_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ (2018) Lysosomal storage diseases. Nat Rev Dis Primers 4(1):27. https:\/\/doi.org\/10.1038\/s41572-018-0025-4","journal-title":"Nat Rev Dis Primers"},{"key":"2546_CR56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biochi.2016.09.011","volume":"130","author":"EM Kuech","year":"2016","unstructured":"Kuech EM, Brogden G, Naim HY (2016) Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders. Biochimie 130:152\u2013162. https:\/\/doi.org\/10.1016\/j.biochi.2016.09.011","journal-title":"Biochimie"},{"issue":"11","key":"2546_CR57","doi-asserted-by":"publisher","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","volume":"5","author":"J Marshall","year":"2010","unstructured":"Marshall J, Ashe KM, Bangari D, McEachern K, Chuang WL, Pacheco J, Copeland DP, Desnick RJ, Shayman JA, Scheule RK, Cheng SH (2010) Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE 5(11):e15033. https:\/\/doi.org\/10.1371\/journal.pone.0015033","journal-title":"PLoS ONE"},{"key":"2546_CR58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, Desnick RJ, Scheule RK, Leonard JP, Cheng SH, Marshall J (2015) Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for fabry disease. Mol Med 21:389\u2013399. https:\/\/doi.org\/10.2119\/molmed.2015.00088","journal-title":"Mol Med"},{"issue":"4","key":"2546_CR59","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Guerard","year":"2018","unstructured":"Guerard N, Oder D, Nordbeck P, Zwingelstein C, Morand O, Welford RWD, Dingemanse J, Wanner C (2018) Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther 103(4):703\u2013711. https:\/\/doi.org\/10.1002\/cpt.790","journal-title":"Clin Pharmacol Ther"},{"key":"2546_CR60","first-page":"O-09","volume":"9","author":"PGDP Deegan","year":"2019","unstructured":"Deegan PGDP, Goker-Alpan O, Geberhiwot T, Hopkin RJ, Lukina E, Tylki-Szymanska A, Sensinger C, Gaemers S, DasMahapatra P, Modur V, Zaher A, Wilcox W (2019) Three year open label phase 2a investigation of venglustat safety and exploratory efficacy in classic Fabry patients. JIMD 9:O-09","journal-title":"JIMD"},{"key":"2546_CR61","first-page":"P053","volume":"1","author":"YCS Lee","year":"2019","unstructured":"Lee YCS, Li P, Chen Y, Wang S, Liu P, Niu D (2019) Development of a gene therapy for Fabry disease using adeno-associated viral vector mediated gene transfer. JIMD 1:P053","journal-title":"JIMD"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02546-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02546-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T20:03:13Z","timestamp":1626120193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02546-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2546"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02546-3","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}